Market Overview

Baxter Unveils Olimel 7.6% High Protein Parenteral Nutrition Formulation at the 2018 ESPEN Congress

Share:
  • Highest protein and lowest glucose formulation among Parenteral
    Nutrition (PN) products, available in a standardized, triple-chamber
    bag
    1,2,3,4
  • New PN formulation will help meet needs of high stress patients who
    require more protein and are often impacted by hyperglycemia
  • OLIMEL 7.6% is the latest addition to Baxter's olive oil-based
    parenteral nutrition portfolio
  • Currently approved in Canada, Baxter plans a global launch in 2019

Baxter International Inc. (NYSE:BAX), a global leader in clinical
nutrition, is showcasing OLIMEL 7.6%, the latest addition to the
company's olive oil-based parenteral nutrition portfolio, at the 40th
Congress of the European Society of Clinical Nutrition and Metabolism
(ESPEN), taking place from September 1 to 4. Currently approved in
Canada, OLIMEL 7.6% is a ready-to-use solution designed to meet the
needs of high stress patients by combining the highest protein with the
lowest glucose formulation available in a standardized, triple-chamber
bag.

Critically ill patients and those who have major surgery may require
parenteral nutrition, which may be necessary when a patient cannot get
adequate nutrients orally or through tube feeding. Most of these
patients receive less than half of the protein that is recommended for
more than 10 days in the ICU5. While recent studies show that higher
protein treatments were associated with lower mortality rates in the ICU6,7
giving patients more protein with ready-to-use products can have the
unintended consequence of increasing their intake of glucose and
potentially lead to overfeeding.

"Ready-to-use products containing higher protein may help patients reach
their protein targets, and help them ensure they have the best chance to
survive and recover their quality of life after an ICU stay," explained
Paul Wischmeyer, M.D., professor of Anesthesiology and Surgery at Duke
University School of Medicine. Dr. Wischmeyer is leading several
presentations at ESPEN, including a webinar on the importance of muscle
mass/lean mass and nutrition intervention in the acute care setting and
ICU.

Baxter's latest OLIMEL 7.6% formulation provides clinicians new options
for treating critically-ill patients, as it includes:

  • 76g of protein (amino acid) per liter, designed to deliver protein
    targets in lower fluid volumes.
  • Only 73g of glucose per liter, which helps reduce the risk of
    hyperglycemia.
  • Olive oil-based lipid emulsions that may preserve immune function8,9,10,11,12

"With the addition of the OLIMEL 7.6% formulation, we now offer a
comprehensive PN portfolio to meet the unique needs of high stress
patients," said Jorge Vasseur, general manager of Baxter's Clinical
Nutrition business. "Baxter is focused on advancing innovation for
patients across the hospital and ensuring clinicians have ready access
to nutrition solutions that are designed to help patients recover and
regain their health."

The use of high protein regimens and olive oil-based lipid emulsions are
supported by guidelines from both ESPEN and the American Society for
Parenteral and Enteral Nutrition (ASPEN).

The new OLIMEL formulation is expected to launch globally in 2019. For
more information on OLIMEL, please visit: https://commercialus-site.baxterdigital.net/healthcare-professionals/nutritional-care/olimel-portfolio-nutritional-care

About Baxter's Global Clinical Nutrition Business

Baxter has been assisting clinicians in treating patients' diverse
nutrient needs since the 1940s, when the company first introduced liquid
proteins in the form of amino acids. Since then, Baxter has continued to
advance nutritional therapy. As an example, Baxter pioneered the world's
first "triple-chamber system" internationally for IV nutrition, which
provides many of the essential ingredients of balanced nutrition –
protein, carbohydrates, lipids and electrolytes in a single container --
simplifying the preparation of parenteral nutrition for patients.

Today, Baxter provides one of the broadest parenteral nutrition
portfolios globally, which includes premix IV solutions, vitamins and
lipids, as well as pharmacy workflow management, labeling and
compounding technology. Baxter's lipid emulsions are available globally
in multi-chamber, ready-to-use solutions, and single solution bags that
can be added to a compounded or premixed bag to ensure clinicians can
prescribe the best well-balanced therapy for their individual patients.

About Baxter

Every day, millions of patients and caregivers rely on Baxter's leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we've been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter's employees
worldwide are now building upon the company's rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit www.baxter.com
and follow us on Twitter, LinkedIn and Facebook.

* Important Safety/Risk Information for OLIMEL 7.6%

Therapeutic indications: OLIMEL (amino acids WITH electrolytes,
dextrose, lipids) or (amino acids, dextrose, lipids) is indicated for
parenteral nutrition for adults when oral or enteral nutrition is
impossible, insufficient or contraindicated. Geriatrics: There are no
known differences in safety and effectiveness of parenteral nutrition
formulations in the adult population based upon age. Pediatrics: There
have been no studies performed in the pediatric population.

Contraindications: The use of OLIMEL is contra-indicated in the
following populations/situations: Known hypersensitivity to egg, soybean
products, olive products or any of the active substances, excipients, or
components of the container. Known allergy to corn or corn products
since the products contain corn-derived dextrose, patients with acute
renal failure and without undergoing renal replacement therapy, patients
with severe liver failure or hepatic coma, congenital abnormalities of
amino acid metabolism, severe hyperlipidemia or severe disorders of
lipid metabolism characterized by hypertriglyceridemia,
hypertriglyceridemia-associated acute pancreatitis, severe
hyperglycemia. Additional contraindications specific to OLIMEL
formulations with electrolytes: hyperkalemia, hypercalcaemia,
hyperphosphatemia, hypernatremia, hypermagnesemia, ceftriaxone must not
be administered simultaneously with intravenous calcium-containing
solutions, including OLIMEL, through the same infusion line (e.g. via
Y-site) because of the risk of precipitation of ceftriaxone-calcium salt.

This release includes forward-looking statements concerning current
and existing OLIMEL product formulations (including OLIMEL 7.6%).
Those
statements include potential benefits associated with the use of these
products and anticipated market launch dates (for future OLIMEL
formulations). The statements are based on assumptions about many
important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking
statements: satisfaction of regulatory and other requirements; actions
of regulatory bodies and other governmental authorities; product
quality, manufacturing or supply, or patient safety issues; changes in
law and regulations; and other risks identified in Baxter's most recent
filing on Form 10-K and other SEC filings, all of which are available on
Baxter's website. Baxter does not undertake to update its
forward-looking statements.

Olimel and Baxter are registered trademarks of Baxter International Inc.

###

1 OLIMEL N12 SmPC, 2017.
2 SmofKabiven SmPC, 2017.
3 NutriFlex
SmPC, 2015
4 Trimix HP SmPC, 2017.
5 Hoffer and Bistrian. Am J
Clin Nutr 2012;96:591–600.
6 Elke G et al. Critical Care
2014;18:R29.
7 Allingstrup Clinical Nutrition 2012;32: 460=18.
8
Jia Nutrition Journal 2015;14-119.
9 Calder PC, et al. Intensive
Care Med 2010;36:735-49.
10 Granato D, et al. JPEN J Parenter
Enteral Nutr 2000;24:113-8.
11 Olthof E, et al. Clin Nutr
2013;32:643-649. 4. Pontes-Arruda A, Clin Nutr Suppl 2009;4:19-23. 5.
12
Waitzberg DL, et al. JPEN J Parenter Enteral Nutr 2006;30:351-67.

View Comments and Join the Discussion!